Bioventix Plc Director/PDMR Shareholding
19 November 2016 - 5:01AM
UK Regulatory
TIDMBVXP
Bioventix plc
("Bioventix" or the "Company")
Director/PDMR Shareholding
Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for application in
clinical diagnostics, was notified on 18 November 2016 of the following
transactions in its ordinary shares of 5 pence each ("Ordinary Shares"):
Director Position Ordinary Sale price Ordinary Percentage
Shares per Shares held of issued
sold Ordinary subsequently share
Share capital held
subsequently
Ian Nicholson and Non-Executive 4,000 1300p 23,000 0.45%
Persons Closely Chairman
Associated
Peter Harrison and CEO 100,000 1300p 508,176 9.96%
Persons Closely
Associated
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities /
person closely associated
a) Names Ian Nicholson (Non-Executive Chairman)
Catherine Nicholson (PCA of Ian Nicholson)
Peter Harrison (CEO)
Abigail Harrison (PCA of Peter Harrison)
Reason for the Notification
a) Position/status See 1(a) above, all are PDMR's or PCA's of
PDMR's
b) Initial notification/ Initial notification
Amendment
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Bioventix plc
b) LEI n/a
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of the Ordinary shares of 5 pence ("Ordinary
Financial instrument, Shares")
type of instrument
Identification code GB00B4QVDF07
b) Nature of the In each case, sale of Ordinary Shares
transaction
c) Price(s) and volume(s) Ian Nicholson:
Price(s) Volume(s)
1300 pence 2,000
Catherine Nicholson:
Price(s) Volume(s)
1300 pence 2,000
Peter Harrison:
Price(s) Volume(s)
1300 pence 98,000
Abigail Harrison:
Price(s) Volume(s)
1300 pence 2,000
d) Aggregated information: Sale of 2,000 Ordinary Shares at a price of
1300 pence per Ordinary Share
Sale of 2,000 Ordinary Shares at a price of
1300 pence per Ordinary Share
Sale of 98,000 Ordinary Shares at a price of
1300 pence per Ordinary Share
Sale of 2,000 Ordinary Shares at a price of
1300 pence per Ordinary Share
e) Date of the transaction 18 November 2016
f) Place of the London Stock Exchange, AIM Market (XLON)
transaction
For further information please contact:
Bioventix plc Tel: 01252 728 001
Peter Harrison Chief Executive Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Simon Hicks Corporate Finance
Stephen Norcross Corporate Broking
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.
END
(END) Dow Jones Newswires
November 18, 2016 13:01 ET (18:01 GMT)